Nalaganje...
RETRACTED ARTICLE: Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma
Idelalisib, a selective PI3Kδ inhibitor, has been approved by the FDA for chronic lymphocytic leukemia/small lymphocytic lymphoma treatment and for follicular lymphoma treatment when combined with rituximab. However, the mechanisms of effective action of idelalisib in hepatocellular carcinoma (HCC)...
Shranjeno v:
| izdano v: | Cell Death Dis |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6141589/ https://ncbi.nlm.nih.gov/pubmed/30224718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0960-8 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|